Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Miyazaki, Tetsuro ^a   Shimada, Kazunori ^a   Miyauchi, Katsumi ^a   Kume, Atsumi ^a   Tanimoto, Kosei ^a   Kiyanagi, Takashi ^a   Sumiyoshi, Katsuhiko ^a   Hiki, Makoto ^a   Mokuno, Hiroshi ^a   Okazaki, Shinya ^a   Sato, Hitoshi ^a   Kurata, Takeshi ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

ADULT; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; LIPID BLOOD LEVEL; MALE; PARTICLE SIZE; PERCUTANEOUS CORONARY INTERVENTION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; BLOOD; DRUG EFFECT; DRUG ELUTING STENT; HYPERPLASIA; LIPID METABOLISM; MIDDLE AGED; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG-ELUTING STENTS; FEMALE; FENOFIBRATE; HUMANS; HYPERPLASIA; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED;

EID: 77958134546     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-122     Document Type: Article

References (33)

1. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. MJ Chapman, Atherosclerosis 2003 171 1 13 10.1016/S0021-9150(03)00156-4 14642400
2. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. HB Rubins SJ Robins D Collins CL Fye JW Anderson MB Elam FH Faas E Linares EJ Schaefer G Schectman TJ Wilt J Wittes, N Engl J Med 1999 341 410 418 10.1056/ NEJM199908053410604 10438259
3. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Diabetes Atherosclerosis Intervention Study (DAIS) investigators, Lancet 2001 357 905 910 10.1016/S0140-6736(00)04209-4 11289345
4. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. A Keech RJ Simes P Barter J Best R Scott MR Taskinen P Forder A Pillai T Davis P Glasziou P Drury YA Kesaniemi D Sullivan D Hunt P Colman M d'Emden M Whiting C Ehnholm M Laakso, Lancet 2005 366 1849 10.1016/S0140-6736(05)67667-2 16310551
5. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. PJ Barter HB Brewer Jr MJ Chapman CH Hennekens DJ Rader AR Tall, Arterioscler Thromb Vasc Biol 2003 23 160 167 10.1161/01.ATV.0000054658.91146.64 12588754
6. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. R Krishna MS Anderson AJ Bergman B Jin M Fallon J Cote K Rosko C Chavez-Eng R Lutz DM Bloomfield M Gutierrez J Doherty F Bieberdorf J Chodakewitz KM Gottesdiener JA Wagner, Lancet 2007 370 1907 1914 10.1016/S0140-6736(07)61813-3 18068514
7. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. J Kobayashi H Okamoto M Otabe H Bujo Y Saito, Atherosclerosis 2002 162 131 135 10.1016/S0021-9150(01)00705-5 11947906
8. Effects of torcetrapib in patients at high risk for coronary events. PJ Barter M Caulfield M Eriksson SM Grundy JJ Kastelein M Komajda J Lopez-Sendon L Mosca JC Tardif DD Waters CL Shear JH Revkin KA Buhr MR Fisher AR Tall B Brewer, N Engl J Med 2007 357 2109 10.1056/NEJMoa0706628 17984165
9. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. B Zhang P Fan E Shimoji H Xu K Takeuchi C Bian K Saku, Arterioscler Thromb Vasc Biol 2004 24 1910 1915 10.1161/01.ATV.0000143389.00252.bc 15331428
10. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. RJ Bisoendial GK Hovingh K El Harchaoui JH Levels S Tsimikas K Pu AE Zwinderman JA Kuivenhoven JJ Kastelein ES Stroes, Arterioscler Thromb Vasc Biol 2005 25 133 e134 10.1161/01.ATV.0000179009.60612. 28 16127020
11. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. AH Klerkx K El Harchaoui WA van der Steeg SM Boekholdt ES Stroes JJ Kastelein JA Kuivenhoven, Arterioscler Thromb Vasc Biol 2006 26 706 715 10.1161/01.ATV.0000205595.19612.c9 16439711
12. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. M Guerin E Bruckert PJ Dolphin G Turpin MJ Chapman, Arterioscler Thromb Vasc Biol 1996 16 763 772 8640404
13. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. IJ Jonkers AH Smelt H Hattori LM Scheek T van Gent FH de Man A van der Laarse A van Tol, J Lipid Res 2003 44 1462 1479 10.1194/jlr.M300008-JLR200 12754275
14. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. M Guerin W Le Goff E Frisdal S Schneider D Milosavljevic E Bruckert MJ Chapman, J Clin Endocrinol Metab 2003 88 3738 3746 10.1210/jc.2003-030191 12915663
15. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. CC van der Hoogt W de Haan M Westerterp M Hoekstra GM Dallinga-Thie JA Romijn HM Princen JW Jukema LM Havekes PC Rensen, J Lipid Res 2007 48 1763 1771 10.1194/jlr.M700108-JLR200 17525476
16. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. A Jeremias A Kirtane, Ann Intern Med 2008 148 234 238 18087049
17. Prevention of restenosis by bezafibrate after successful coronary angioplasty. S Ishiwata S Nakanishi S Nishiyama A Seki, Coron Artery Dis 1995 6 883 889 8696533
18. Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. T Kasai K Miyauchi T Yokoyama K Aihara H Daida, Atherosclerosis 2006 188 274 280 10.1016/j.atherosclerosis.2005.10.047 16325819
19. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. B Staels W Koenig A Habib R Merval M Lebret IP Torra P Delerive A Fadel G Chinetti JC Fruchart J Najib J Maclouf A Tedgui, Nature 1998 393 790 793 10.1038/31701 9655393
20. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. P Delerive K De Bosscher S Besnard W Vanden Berghe JM Peters FJ Gonzalez JC Fruchart A Tedgui G Haegeman B Staels, J Biol Chem 1999 274 32048 32054 10.1074/jbc.274.45.32048 10542237
21. A potent activator of PPARalpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits. N Seki H Bujo M Jiang M Shibasaki K Takahashi N Hashimoto Y Saito, Atherosclerosis 2005 178 1 7 10.1016/j.atherosclerosis.2004.08.015 15585194
22. PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. F Gizard C Amant O Barbier S Bellosta R Robillard F Percevault H Sevestre P Krimpenfort A Corsini J Rochette C Glineur JC Fruchart G Torpier B Staels, J Clin Invest 2005 115 3228 3238 10.1172/JCI22756 16239970
23. Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease. T Miyazaki K Shimada O Sato K Kotani A Kume K Sumiyoshi Y Sato H Ohmura Y Watanabe H Mokuno H Daida, Atherosclerosis 2005 179 139 145 10.1016/j.atherosclerosis.2004.09.013 15721020
24. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus, J Jpn Diabetes Soc 2010 53 450 467
25. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. S Usui Y Hara S Hosaki M Okazaki, J Lipid Res 2002 43 805 814 11971952
26. Enhanced production of nitric oxide, reactive oxygen species, and pro-inflammatory cytokines in very long chain saturated fatty acid-accumulated macrophages. N Yanagisawa K Shimada T Miyazaki A Kume Y Kitamura K Sumiyoshi T Kiyanagi T Iesaki N Inoue H Daida, Lipids Health Dis 2008 7 48 10.1186/1476-511X-7-48 19038055
27. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. H Yokoi H Daida Y Kuwabara H Nishikawa F Takatsu H Tomihara Y Nakata Y Kutsumi S Ohshima S Nishiyama A Seki K Kato S Nishimura T Kanoh H Yamaguchi, J Am Coll Cardiol 1997 30 855 862 10.1016/S0735-1097(97)00270-2 9316509
28. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. XC Jiang LB Agellon A Walsh JL Breslow A Tall, J Clin Invest 1992 90 1290 1295 10.1172/JCI115993 1401066
29. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. M Westerterp CC van der Hoogt W de Haan EH Offerman GM Dallinga-Thie JW Jukema LM Havekes PC Rensen, Arterioscler Thromb Vasc Biol 2006 26 2552 2559 10.1161/01.ATV. 0000243925.65265.3c 16946130
30. Lack of stimulation of cholesteryl ester transfer protein by cholesterol in the presence of a high-fat diet. SK Cheema A Agarwal-Mawal CM Murray S Tucker, J Lipid Res 2005 46 2356 2366 10.1194/jlr.M500051-JLR200 16106052
31. Measurement issues related to lipoprotein heterogeneity. JD Otvos EJ Jeyarajah WC Cromwell, Am J Cardiol 2002 90 22i 29i 10.1016/S0002-9149(02)02632- 2 12419478
32. High-density lipoprotein subpopulations in pathologic conditions. BF Asztalos EJ Schaefer, Am J Cardiol 2003 91 12E 17E 10.1016/S0002-9149(02)03383-0 12679198
33. Restenosis revisited - new targets, new therapies. P Libby P Ganz, N Engl J Med 1997 337 418 419 10.1056/NEJM199708073370608 9241132